Category Archives: Pharmaceuticals

NICOTINE / COTININE RAPID URINE TEST KIT-Nano-Check™ FROM USA – FDA APPROVED

NICOTINE / COTININE RAPID URINE TEST KIT-Nano-Check™ FROM USA – FDA APPROVED

{TO BE USED FOR: PRE-INSURANCE POLICY CHECKUP /
EMPLOYMENT SCREENING / CLINICAL TRIALS}

 The Nano-Check™ Nicotine test is a rapid, self-controlled immunoassay for the qualitative detection of cotinine in human urine. Cotinine is a primary metabolite of nicotine and remains in the body of habitual tobacco users for approximately 17 hours. The cutoff concentration of this test is 200 & 500 ng/ml of cotinine. This in-vitro assay is intended for professional use.

{cotinine levels more than 10 ng/mL are considered to be consistent with no active smoking. Values of 10 ng/mL to 100 ng/mL are associated with light smoking or moderate passive exposure, and levels above 300 ng/mL are seen in heavy smokers – more than 20 cigarettes a day. In urine, values between 11 ng/mL and 30 ng/mL may be associated with light smoking or passive exposure, and levels in active smokers typically reach 500 ng/mL or more.)

Easy to use

• Simple one step assay

• Urine based immunochromatography

• Small sample volume, 80 ul

• Result read visually

• With Nano-Checker 710 reader, results are automatically determined and displayed    or printed as “Positive” or “Negative”

• Accurate and Consistent Quality 

• Rigorous Quality Control system

• FDA Approved

 

We are offering Nicotine / Cotinine Urine Rapid Test Kits.

More info: contact us on  022-26731904 / 26731052 Ext # 35

  Or write us on :

 santosh.sahu@pammvi.com/mansi.gurav@pammvi.com/enquiry@pammvi.com

 Pammvi Group Of Companies

C-501, Remi Bizcourt, 9, Shah Ind Estate,

V.D Road, Andheri (w), Mumbai – 53.

Board: 022-26731904 / 26731052 Ext # 35

Fax: 022-26731901

http://www.pammvi.com/divisions.aspx?catid=9

http://www.nicotine-test.blogspot.com/

ChiroSolve, Inc. Launches New Method Development Kits

Santa Clara, CA. – February 4, 2011- CHIROSOLVE INC., continues to enhance the world of enantiomeric separation with the introduction of two new customer-centric packaged solutions, EnantioPrep and ScalePrep, that are intended for high efficiency chiral separation of enantiomers. They offer seamless transition from identification of initial separation conditions to fully optimized method development within a matter of days.

ChiroSolve has been very successful in producing a line of chiral kits tailor made for scientists at different stages of their research. EnantioPrep includes a set of ChiroSolv™ kits to be used in a simple 3-step process. The kits employ ChiroSolve’s patented approach to comprehensively screen 384 separation conditions providing the knowhow for a successful outcome. The use of this package results in the identification of a complete step by step, time, cost and resource efficient procedure and an enantiopure compound. This product is especially useful for scientists in the early stages of drug discovery.  ScalePrep is targeted at those scientists looking to produce larger amounts of pure product with the identification of an ideal production route that can be scaled up to provide kilo quantities of highest enantiomeric purity. ChiroSolve also offers a set of relevant services to complement these products.

The company has recently developed a fully automated system to handle this entire process from the initial screening to finding the optimal synthetic route. If you are interested in being among the first of many to gain access to this new technology, contact ChiroSolve at info@chirosolve.com or call us at (408) 834-8597. You can learn more about ChiroSolve and its products and services at the company’s website: www.chirosolve.com.

Molplex and Enamine Announce a New Partnership

Newcastle, UK and Kiev, Ukraine. January 24th 2010 – Molplex and Enamine today announced a new partnership to offer the Enamine screening collection of 1.8 million stock chemicals through the Molplex online drug design and assay-ready chemical supply services. The agreement is a major step towards eliminating the high start-up costs ofdrug discovery, bringing sophisticated drug design, compound management and assay-ready chemistry to the world’s drug discovery scientists on demand. The agreement adds Molplex online drug design systems to the deep experience in organic chemistry and compound management of Enamine to solve the problem of generating viable chemical leads for novel targets.

Molplex CEO David E. Leahy said: “We are very proud to be selected by Enamine as their partner for on demand drug discovery services at a time when major restructuring of the industry is creating new opportunities and new markets for our combined expertise. This agreement marks a step change in the size and scope of our assay-ready chemical supply service and major progress towards our goal of being the world’s first choice partner for enabling the long tail of drug discovery”

Enamine Chief Marketing and Sales Officer Dr Vladimir Ivanov said “We are happy to partner with Molplex and supply our products to the highly integrated drug discovery platform they maintain. In this collaboration we deploy all our discovery resources including the world’s biggest screening collection (1.8 million compounds), largest inventory of building blocks (45,000 products), and over 300 chemists at our Kiev’s site to assure high cost efficiency and high responsiveness to any follow up chemistry emerging from projects run through Molplex discovery platform.”

About Molplex
Molplex was created by David Leahy and Vladimir Sykora to help anyone anywhere in the world invent new medicines. Molplex’s ambition is to eliminate the high set up costs of drug discovery providing the sophisticated online drug design systems integrated with assay ready chemical supply and high content screening. CEO David Leahy previously founded Cyprotex PLC, now the world’s largest ADME Tox service supplier. The Molplex team offers extensive drug discovery experience and sophisticated software systems for automated drug design. Molplex goal is to enable the long tail of drug discovery to provide the new medicines of tomorrow by eliminating the cost of entry and increasing success rate of drug discovery projects

For more information visit www.molplex.com.

About Enamine
Enamine has been established as a provider of research services to the pharmaceutical and biotechnology industry since 1991 and is the world’s largest chemistry supplier of innovative compound libraries and building blocks to the pharmaceutical industry.

For more information on Enamine visit www.enamine.net

Contact Details:

David Leahy, CEO,
Molplex Ltd.
i6 Charlotte Square
Newcastle Upon Tyne
England, NE1 4XF
info@molplex.com
Tel: US: 1-408-905-2900
Europe : 44-191-211-196
Dr Vladimir Ivanov, Chief Marketing and Sales Officer
ENAMINE Ltd.
23 Alexandra Matrosova Street
01103 Kiev, Ukraine
v.ivanov@enamine.net
Tel: +38 044 537 32 18
Fax: +38 044 537 32 53

Gene Therapy and Stem Cell Therapy Standard Developed For A Unique Derivative Of Post Hetero-Plastic Inplantation Chronic Inflammation Syndrome

Researchers task force, led by faculties of T-Protocol, registered Genom Project as controlled genom project in the hosted database of NCBI, a publication matter authority and function assigned organization under oversee of Department of Health & Human Services, reached once to share the exegetical impression officially pre-published concerning the understanding specific spectrum of symptoms covering boroad range of character usually complained and observed through chronic inflammation, granuloma, some types of lymphoma and various uncommon symptoms to let physician scientists suspecting indicium of neurological diseases, NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and setting Massachusetts indications of treatments standardized manual (Massachusetts manual) & diagnostic and standardized medical treatment manual for post hetero-plastic inplantation chronic inflammation syndrome, specific edition against NIDO Disease.

The once defined causes of NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome are considered each of a common living organism to cause conformational diseases like Creutzfeldt-Jakob disease, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and kinds of and a set of biochemical and physical reaction and response realized by cross-species gene- mutation, as biotransformation, easily describing natural physiological and biochemical changes in vivo substrate of human bodies. After this studies, standardized protocol of gene therapy and applied stem cell therapy is now in practice and on available.

Faculties,committing themselves entirely to the project, of each institutes and organizations participating the project to ascertain proteins and DNA/genomic DNA/genom of human, other mammal and virulent microorganism including bacillus/virus affecting each symptom and the symptoms’ spectrum expressed generally and observed commonly on patients suffered from NIDO disease, extraordinarily unique derived type of post hetero-plastic implantation chronic inflammation syndrome and to develop diagnostic standard and treatment protocol standardized and to find a clue compose gene therapy protocol and applied stem cell therapy protocol to entirely heal NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and to let all of current suffered patients from various combined symptoms directly derived by chronic inflammation and various tumors, have to express full surprise at the fact that these disease and patients suffered are made up and left no attention and no relief.

Commissioner of ethics board of the project will agree that this case should be regarded as not agreed human experimentation.

Contact Details: Genom Project Matter: http://www.ncbi.nlm.nih.gov
T-Protocol Treatment Matter: medinfo@vistomail.com
or near RMP accredited issuing referral

Division of Gene Medicine & Stem Cell Application, School of Medical Science Discovers Natural Bio Mechanism Of Hair Regrowth

Division of Gene Medicine & Stem Cell Application, School of Medical Science, complete the research and established completely new protocol totally recovering natural bio mechanism of hair regrowth.

The researchers, led by Lord. Prof. Dr. Daichent Otto Rie, specified protein and genom to affect internal bio mechanism to generate hair and control the level of successful growth being low which is the baldness.

The key cast of the set of the bio cycle is hair follicles, which is stem cell on head skin and effect or holding function to cure many neurotic diseases and disorders like Alzheimer’s disease – Prion Disease and even Trion Disease (Post Hetero-Plastic Implantation Chronic Inflammation Syndrome; PhCIS) has absolutely unique character being retrieved absolute stem cell, which can recover the ability as stem cell after got adult. The key genom and DNA has been found through the Genom Project’s T-Protocol research developing in the government registered Genom Project since 2005. The most concentrated attention of researchers is not “what is cause” but “What protocol is best”.

The team of Prof.Daichent has successfully completed in vivo and in vivro experiment actually using voluntary patients whose types of hair loss being across over highly wide range extent to even lymphoma and cancer and finally established next genetic hair loss curing treatment protocol mainly composed of stem cell therapy and gene therapy.

Most of cases are treatable through entry level stem cell theraputic technique or HIV-1 Vector using high level technique but A20 introduction as gene therapy is required when treating patients being suffered from lymphoma, cancer or any neurotic diseases like Alzheimer’s disease – Prion Disease and even Trion Disease (Post Hetero-Plastic Implantation Chronic Inflammation Syndrome; PhCIS).

As Prof.Daichent points since 2005 being on School of Public Health of Harvard, in the treatment manual (published 2005), the key factor to overcome of lymphoma and chronic inflammation on human skin is extraordinary redundancy coding of polyglutamine DNA synthesis as the type of disease caused by pathological proteins and lack or heavy impairment of an specific DNA of A20.

Actually, the treatment protocol curing for baldness is also found through T-protocol which was essentially aimed at achieving causal and complete treatment of lymphoma, cancer, chronic inflammation and many neurotic diseases. Under control over the T-Protocol, all of clinical practitioner must always keep their eyes on the fact of using steroid is taboo over administration so being strictly prohibited. And also the technique must be under control of the competent faculty accredited by board in accordance with Europ.Gene Institute or specifically set physically area solely for research and clinical practice of nations like Switzerland, Germany, India, Hongkong, U.K. territories (NEVER inside U.K.) appointed by protocol developer and
assigned practice entity.

Absolutely the set of treatment using gene therapy of A20 injection is totally successful and contributes high degree of extension of patients’ life. As ordinary treating way in general and internal medicine, an new drug to treat chronic inflammation, lymphoma and neurotic diseases including Trion Disease has been made up and already delegated the scheme and title to produce forward a Euro.Pharma.co. under preparation distributing for chronic inflammation and lymphoma.

An patient who hopes the treatment by T-Protocol (occasionally consulting Prof.Daichent) could be cared by referral basis.

Contact Details: General Matter: genemed.science@vistomail.com
Genom Project Matter: http://www.ncbi.nlm.nih.gov
T-Protocol Treatment Matter: medinfo@vistomail.com or near RMP accredited issuing referral

‘Drug Discovery On Demand’ Service Launched By David Leahy and Vladimir Sykora From Molplex

England, November 5th 2010 – An innovative new online “drug discovery on demand” platform has been launched by Molplex, a company specializing in products and services for the life sciences. Designed to help drug discovery groups working anywhere in the world, it aims to eliminate the high start-up costs and minimize the financial risks traditionally associated with inventing new medicines.

Molplex CEO David Leahy said: “As the pharmaceutical industry changes, a new ecosystem of small, flexible teams operating as “Micro Pharmas” is emerging. Molplex will provide the services they need to succeed at inventing better medicines at lower cost”.

The first version of the new Molplex system launched today offers free access to sophisticated drug design systems, high quality assay-ready stock chemicals and high content biological screening at www.molplex.com.

Editor’s Note

For more information contact: info@molplex.com, Tel: US:
1-408-905-2900 Europe: 44-191-211-1965 www.molplex.com

About Molplex
Molplex was created by David Leahy and Vladimir Sykora to help anyone anywhere in the world invent new medicines by making sophisticated drug discovery information and laboratory systems available on-line and on demand. CEO David Leahy previously founded Cyprotex PLC, now the world’s largest ADME Tox service supplier. COO Dr Vladimir Sykora has extensive drug discovery experience and has developed sophisticated software systems for automated drug design. They are joined as VP for Asia-Pacific by Dr Brian O’Keeffe who has considerable commercial and senior management experience in drug development including President of Asia-Pacific for Quintiles.

Contact Details: i6, Charlotte Square, Newcastle Upon Tyne, England, NE1 4XF
info@molplex.com US: 1-408-905-2900 Europe: 44-191-211-1965

MDCare EMR / PMS from Vision Infonet Inc RECEIVES ONC-ATCB 2011/2012 CERTIFICATION

Vision Infonet Inc announced today that MDCare EMR, Version 4.2 is 2011/2012 compliant and was certified as an EHR Module on 10/1/2010 in accordance with the applicable ELIGIBLE PROVIDER certification criteria adopted by the Secretary of HHS.

Napeville, IL, October 06, 2010 — Vision Infonet Inc announced today that MDCare EMR, Version 4.2 is 2011/2012 compliant and was certified as an EHR Module on 10/1/2010 by the Certification Commission for Health Information Technology (CCHIT®), an ONC-ATCB, in accordance with the applicable ELIGIBLE PROVIDER certification criteria adopted by the Secretary of Health and Human Services. The 2011/2012 criteria support the Stage 1 meaningful use measures required to qualify eligible providers and hospitals for funding under the American Recovery and Reinvestment Act (ARRA).

“We believe this certification validates that MDCare EMR is the leading EHR software. The eligible providers by using MDCare EMR/PMS technology as part of their criteria to qualify for Center for Medicare and Medicaid Services (CMS) incentive payments to receive $44,000 to $63,750 in federal stimulus dollars by becoming “meaningful users” of EHR Systems.

The American Recovery and Reinvestment Act (ARRA) of 2009 is giving millions of dollars to practise under the HITECH Act that promotes the use and adaption of integrated Electronic Medical Record and Practice Management System.

Starting in 2011, eligible professionals can qualify for government stimulus funds by demonstrating “meaningful use” of certified EHR technology.”

The ONC-ATCB 2011/2012 certification program tests and certifies that Complete EHRs meet all of the 2011/2012 criteria and EHR Modules meet one or more – but not all – of the criteria approved by the Secretary of Health and Human Services (HHS) for either eligible provider or hospital technology. Companies offering ONC-ATCB 2011/2012 certified EHR modules may return to test additional criteria and certify their products as Complete EHRs later. Companies certifying products early in the ONC-ATCB certification process must quickly adapt their products to meet the evolving nature of the NIST test procedures, particularly for electronic prescribing. ONC-ATCB product certification updates will be available at http://www.cchit.org as they occur.

“CCHIT is pleased to be testing and certifying products so that companies are now able to offer these products to providers who wish to purchase and implement certified EHR technology and achieve meaningful use in time for the 2011-2012 incentives,” said Karen M. Bell, M.D., M.S.S., Chair, CCHIT.

2011/2012 certification conferred by CCHIT does not represent an endorsement of the certified EHR technology by the U.S. Department of Health and Human Services nor does it guarantee the receipt of incentive payments.

MDCare EMR/PMS solution is easily accessible from anytime and anywhere cloud application. MDCARE is a proven solution for front office, administrative, clinical, as well as revenue cycle management. “As a result of the investment made in creating an efficient and robust product, we can offer an integrated certified Electronic Health Record and Practice Management System that adapts to the provider’s practice with customization as our key feature.”

MDCARE is a powerful integrated EMR/PM system providing the perfect combination of EHR and Practice Management. From scheduling to billing and point-of-care to reporting, MDCARE optimizes your practice efficiency and patient care, and streamlines patient encounters and the billing processes.

About CCHIT:
The Certification Commission for Health Information Technology (CCHIT®) is approved by the Office of the National Coordinator for Health Information Technology (ONC) of the U.S. Department of Health and Human Services (HHS) as an Authorized Testing and Certification Body (ONC-ATCB). CCHIT®) is an independent, 501(c)3 nonprofit organization with the public mission of accelerating the adoption of robust, interoperable health information technology. The Commission has been certifying electronic health record technology since 2006 More information on CCHIT, CCHIT Certified® products and ONC-ATCB certified electronic health record technology is available at http://cchit.org.

About ONC-ATCB 2011/2012 certification:
The ONC-ATCB 2011/2012 certification program tests and certifies that EHR technology is capable of meeting the 2011/2012 criteria approved by the Secretary of Health and Human Services (HHS). The certifications include Complete EHRs, which meet all of the 2011/2012 criteria for either eligible provider or hospital technology and EHR Modules, which meet one or more – but not all – of the criteria. ONC-ATCB certification aligns with Health Information Technology: Initial Set of Standards, Implementation Specifications, and Certification Criteria for Electronic Health Record Technology published in the Federal Register in July 2010 and strictly adheres to the test procedures published by the National Institute of Standards and Technology (NIST) at the time of testing. ONC-ATCB 2011/2012 certification conferred by the Certification Commission for Health Information Technology (CCHIT®) does not represent an endorsement of the certified EHR technology by the U.S. Department of Health and Human Services nor does it guarantee the receipt of incentive payments.

“CCHIT®” and “CCHIT Certified®” are registered trademarks of the Certification Commission for Health Information Technology.

For more information or to schedule a live demo, please call 1-877-377-8999 ext 21.

Press & Media Contact:
Vijay Prodduturi
Vision Infonet, Inc
1717 Park Street, Suite 110
Napeville, IL 60563
630-299-7638
vijay@v2k.in
http://www.vinfonet.com

Synowledge to Participate in Pacific Drug Safety Summit

Stamford, CT, September 16, 2010 – Synowledge LLC, a market leader in drug safety and pharmacovigilance services and related IT solutions for life sciences organizations of all sizes announced today that Dr. Jacinta Aniagolu Johnson, Director, Pharmacovigilance and Risk Management, will be representing Synowledge at Pacific Drug Safety Summit at San Francisco Airport Marriott, Burlingame, California, USA on 23rd-24th September 2010.

The Pacific Drug Safety Summit will provide half-day training sessions on key drug safety and pharmacovigilance practice areas. Attendees will have the opportunity to participate in networking breaks and interact with a diverse gathering of US and EU drug safety and pharmacovigilance practitioners, service providers, and vendors.

Conference Details: Pacific Drug Safety Summit

Date & Time: September 23-24, 2010, 8.30 am – 5.00pm Pacific Time

Location: San Francisco Airport Marriott, Burlingame, California, USA

Pre-Conference Tutorial #2: Risk Evaluation and Mitigation Strategies (REMS)

An Overview of Current Regulations and Approach to Documentation and Preparation
Speaker: Dr. Jacinta Aniagolu Johnson, Director, EU PV and Risk Management

Description: A full agenda of contemporary, cutting-edge pharmacovigilance topics from nine experienced speakers in the pharmacovigilance and risk management field.

Dr. Jacinta, along with Mark Loudon from Aris Global, will present an overview of current regulations and approaches to documentation and preparation. The goal will be to provide users with information about practical mechanisms at both the strategic and operational level to help demystify and apply proper risk management methods.

Topics include:

  • Practical Elements for Risk Management
  • FDAAA
  • Relationship between REMS and RiskMAPs
  • FDA REMS template
  • REMS contents
  • Highlights of the FDA draft REMS Guidance, and examples of FDA-approved proposed REMS

About Dr. Jacinta Aniagolu Johnson

Dr. Jacinta Aniagolu is a trained biomedical and clinical research scientist, an AE/ADR signal analysis and pharmacovigilance, risk management and drug safety surveillance subject matter expert. She has 17 years combined expertise and cross-functional knowledge in biomedical and clinical drug development research, drug safety surveillance, pharmacovigilance, and risk management. Currently, as the Director, Pharmacovigilance and Risk Management, at Synowledge, Dr. Aniagolu directs client Pharmacovigilance and Risk Management project activities. She provides leadership, guidance and subject matter expertise in the areas of Drug Safety and Pharmacovigilance, and medical/scientific affairs.

About Synowledge

Synowledge is a global provider of drug safety and pharmacovigilance services and related IT solutions to small, mid and large size pharmaceutical and biotechnology companies. Our comprehensive outsourcing solutions combine the unique strengths of both onshore and offshore services to meet all our clients’ needs. With more than 15 years of industry experience, our core team members have worked with leading pharmaceutical, biotech, medical device and health provider organizations. We have our headquarters located in Stamford CT, USA and additional offices in Bangalore, India and the United Kingdom. For more information, please visit www.synowledge.com.

###

Synowledge Announces 15 New Customer Wins Worldwide

LONDON — August 30, 2010 – Synowledge LLC, a market leader in drug safety and pharmacovigilance services and related IT solutions for life sciences organizations of all sized announced its largest customer win growth to-date. Synowledge signs 15 new customers in 2010 (including a fortune 100 company and a top 20 pharma company). These new accounts outline Synowledge’s accelerating growth in its customer base and revenues.

Synowledge’s proven ability to provide its customers with quality services is evident in this double digit customer account growth. Synowledge’s growth in customer wins was spurred by the expansion of its global customer base – as well as Synowledge’s excellent service to existing customers.

In the past one year, Synowledge has dramatically increased its customer base with a number of new customers, including a fortune 100 company and a top 20 pharma company across the globe. In addition, existing Synowledge customers continued to upgrade and expand their usage of Synowledge solutions. Synwoledge’s strategic direction and customer-focused approach continue to drive the company’s innovation and growth.

“Synowledge, backed by its strong expertise in drug safety, PV and IT solutions, continues to invest proactively in the strategic expansion of its solution suite. Our solutions continue to be chosen over those offered by some of the largest service providers in the industry,” said David Ingraham, Director, Marketing & Sales.

About Synowledge

Synowledge is a global provider of drug safety and pharmacovigilance services and related IT solutions to small, mid and large size pharmaceutical and biotechnology companies. Our comprehensive outsourcing solutions combine the unique strengths of both onshore and offshore services to meet all our clients’ needs. With more than 15 years of industry experience, our core team members have worked with leading pharmaceutical, biotech, medical device and health provider organizations. We have our headquarters located in Stamford CT, USA and additional offices in Bangalore, India and the United Kingdom. For more information, please visit www.synowledge.com.

###

Synowledge Continues Global Expansion with New Offices in UK and USA

LONDON — August 30, 2010 – Synowledge LLC, the market leader in drug safety and pharmacovigilance services and related IT solutions for life sciences organizations announced its inauguration of two new offices in Brentford, UK and Columbus OH, USA as part of its ongoing global growth strategy. These two new offices will act as strategic development centers and will also provide support services to Synowledge’s expanding client-base in the US and UK markets. The office addresses are given below:

UK Office Address:

Synowledge UK Limited

1000 Great West Road

Brentford, TW8 9HH

United Kingdom

USA Office Address:

1900 Polaris Parkway, Suite 450

Columbus, Ohio

43240

The decision to establish these two new offices in the US and UK is a result of the significant customer wins Synowledge has experienced in 2010. The expertise of Synowledge’s professionals and their ability to work closely with its customers as a trusted partner have resulted in significant growth in customer base and enhanced level of interest in our solutions.

The USA and UK region is a key market for Synowledge, and we recognize how important these two new facilities are for both our existing business initiatives and future strategic campaigns in the region. In addition to meeting current challenges for Synwoledge’s strategic growth, these two facilities will allow Synowledge to deliver superior sales and support to our customers and to the growing prospect base in the regions.

“We have seen a growing need from our clients in these two regions. Strengthening our presence in key regions around the globe is among a number of current programs we have launched to improve our customer service and build stronger relationships with our customers around the world.” said David Ingraham, Director, Marketing & Sales, “Since embarking on its worldwide strategic expansion plan in 2006, Synowledge is committed to deliver on technology innovation by continually improving our ability to service our current and new clients’ needs.”

About Synowledge

Synowledge is a global provider of drug safety and pharmacovigilance services and related IT solutions to small, mid and large size pharmaceutical and biotechnology companies. Our comprehensive outsourcing solutions combine the unique strengths of both onshore and offshore services to meet all our clients’ needs. With more than 15 years of industry experience, our core team members have worked with leading pharmaceutical, biotech, medical device and health provider organizations. We have our headquarters located in Stamford CT, USA and additional offices in Bangalore, India and the United Kingdom. For more information, please visit www.synowledge.com.

###